Using C. elegans Forward and Reverse Genetics to Identify New Compounds with Anthelmintic Activity.

Area of Science:

• Parasitology
• Drug Discovery
• Nematology

Background:

• Increasing nematode resistance to current anthelmintics poses a threat to human health and food security.
• Existing nematicides often present environmental hazards.
• A need exists for novel, effective, and safe anthelmintic agents.

Purpose of the Study:

• To develop and implement a high-throughput screening (HTS) platform for identifying new anthelmintic drug candidates.
• To utilize the nematode Caenorhabditis elegans as a surrogate model for infectious nematodes in drug discovery.
• To address the critical need for cost-effective and timely identification of novel anthelmintics.

Main Methods:

• A high-throughput screening platform was employed to screen over 26,000 compounds from chemical libraries.
• Phylogenetic profiling was used to assess the relative sensitivity of C. elegans compared to yeast and mammalian cells.
• Drug-resistant C. elegans strains were tested to identify compounds with potentially novel mechanisms of action.

Main Results:

• 14 potential new anthelmintic compounds were identified from the screened chemical libraries.
• A subset of these compounds demonstrated selective sensitivity in C. elegans, suggesting potential as anthelmintics.
• One identified compound was found to target mitochondrial complex II, with structural analysis providing insights into its differential effects.

Conclusions:

• The HTS approach using C. elegans as a surrogate is effective for rapid and specific screening of large compound collections.
• This method aids in identifying anthelmintics with potentially novel mechanisms, distinct from existing drugs.
• The developed platform is crucial for replenishing the pipeline of nematicides to combat resistance and environmental concerns.